Académique Documents
Professionnel Documents
Culture Documents
special article
European Institute of Oncology, Milan, Italy; 22Brustzentrum der Universitt Mnchen, Munich, Denmark; 23Screening and Test Evaluation Program, School of Public Health,
Sydney Medical School, University of Sydney, Sydney, Australia; 24Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, USA; 25Sheba
Medical Center, Tel Hashomer, Israel; 26Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; 27Europa Donna Cyprus, Nicosa, Cyprus;
28
AdvancedBC.org, New York; 29University of Michigan Medical School and School of Public Health, Ann Arbor, USA; 30Europa Donna Sweden &
Brstcancerfreningarnas Riksorganisation, BRO, Sundbyberg, Sweden; 31Oncology Institute of Southern Switzerland and Breast Unit of Southern Switzerland, Bellinzona,
Switzerland; 32Department Medical Oncology, Division of Womens Cancers, Dana-Farber Cancer Institute, Boston, USA; 33Jean Perrin Centre, Comprehensive Cancer
Centre, Clermont Ferrand, France; 34Department of Medicine, Institut Jules Bordet, Brussels, Belgium; 35Department of Medicine, Breast Oncology Program, UCSF Helen
Diller Family Comprehensive Cancer Center, San Francisco; 36Indiana University Medical CTR, Indianapolis, USA; 37Department of Gynaecology, Martin-Luther-University
Halle-Wittenberg, Halle an der Saale, Germany; 38Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA; 39Sandton
Oncology Centre, Johannesburg, South Africa; 40Department of Radiotherapy, Clinique des Grangettes, Geneva, Switzerland; 41Nursing Division, Health Board, Cardiff and
Vale University, Cardiff, UK; 42Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
equally reasonable
globally. These guidelines are developed as a joint effort from
ESO and ESMO (European Society of Medical Oncology), are
Implications
endorsed by EUSOMA (European Society of Breast Cancer
values
values
Specialists), SIS (Senologic International Society), and Flam
(Federacin Latino Americana de Mastologia), and organized
under the auspices of UICC (Union Internationale Contre
observational studies
observational studies
methodology
Prior to the ABC2 Conference, a set of preliminary recommendation state-
ments on the treatment of ABC were prepared, based on available
published data and following the ESMO guidelines methodology. These
recommendations were circulated to all 43 panel members by email for
Benefits clearly outweigh risk
sus session of ABC2. All panel members were instructed to vote on all
questions, with members with a potential conict of interest or who did
not feel comfortable answering the question (e.g. because it is not their
Table 1. Levels of evidence grading system [15]
in the wording of statements were made during the session. The state-
ment on everolimus was updated after the presentation of the overall sur-
vival results of the BOLERO-2 trial and re-voted by email by all panel
1C/strong recommendation, low-
members.
2C/weak recommendation, low-
moderate-quality evidence
1A/strong recommendation,
1B/strong recommendation,
Grade of recommendation/
2B/weak recommendation,
members of the ABC2 consensus panel and their disclosure of any relation-
high-quality evidence
quality evidence
quality evidence
| Cardoso et al.
Annals of Oncology special article
I. general guidelines A patient navigator can help the patient going through all
phases of the cancer journey [1620]. This is particularly rele-
vant for advanced cancer patients who are often overwhelmed
with difcult decisions to make, through complex information
Guideline statement LoE Consensus and available treatment options, and are frequently co-
managed by the breast cancer and the palliative care teams.
All ABC patients should be IB 97.2% (36) yes
This role is best taken by a specialized breast nurse, or at least a
offered comprehensive, 0% (0) abstain
specialized oncology nurse, who should be part of the multi-
culturally sensitive, up-to- (37 voters)
disciplinary team managing ABC patients. In some countries,
date, and easy to understand
however, this role may be played by a physician assistant or
information about their
disease and its management.
another trained and specialized health-care practitioner. It is also
Specialized oncology nurses (if Expert opinion 92.1% (35) yes
recognized that, in many centres, it is not yet possible for each
possible specialized breast 7.8% (3) abstain patient to have a navigator due to the lack of human resources.
nurses) should be part of the (38 voters) There is an implicit assumption that the recording of adverse
multidisciplinary team events by clinicians reliably documents patients side-effects and
managing ABC patients. In symptoms. However, there is an accumulating body of evidence
some countries, this role suggesting that the frequency and severity of many symptoms
may be played by a that impact on an individual patients quality of life go under-
physician assistant or other reported, under-recognized, and consequently under-treated
doi:10.1093/annonc/mdu385 |
special article Annals of Oncology
Survivorship in ABC Current terminology uses several ill-dened terms that often
The complex needs of patients living with ABC, at times for have different meanings, leading to confusion and difculty in
many years, as well as their caregivers, should be addressed not adapting clinical trial ndings to current practice populations.
only in terms of supportive and palliative care but also regarding The ABC2 panel tried to dene two of these important terms,
survivorship concerns. The multidisciplinary approach of ABC aiming at standardization of their use.
should encompass early in the history of the disease not only Regarding endocrine resistance, an attempt was made to be
physical, but also functional, social, psychological, and spiritual, consistent with a denition reached by a number of investigators
domains [2527]. involved in breast cancer clinical trials, at a meeting sponsored
It is important to clearly dene the disease context with by NCI held in May 2012 and later approved by the North
patients and families, addressing the concept of uncertainty and American Breast Cancer Groups (NABCGs).
tailoring the treatment strategy according to individual priorities It is also important to note that endocrine resistance is a con-
and disease status [28]. Specic psychosocial needs of young tinuum, and that strict denitions are mainly helpful for the clin-
and elderly patients should also be recognized and supported, ical trial setting and not necessarily for routine clinical practice.
i.e. social security, job exibility, rehabilitation, body image
(including sexuality), home, and child care. III. inoperable locally advanced,
non-inammatory, breast cancer
II. important ABC-related denitions
Guideline statements LoE Consensus Before starting any therapy, a IB 97.2% (36) yes
core biopsy providing 2.7% (1) abstain
Visceral crisis is defined as Expert opinion 95.0% (38) yes
histology and biomarker (ER, (37 voters)
severe organ dysfunction as 5.0% (2) abstain
PR, HER-2, and
assessed by signs and (40 voters)
proliferation/grade)
symptoms, laboratory
expression is indispensable
studies, and rapid
to guide treatment decisions.
progression of disease.
Since LABC patients have a IB 100% (37) yes
Visceral crisis is not the
significant risk of metastatic 0% (0) abstain
mere presence of visceral
disease, a full staging (37 voters)
metastases, but implies
workup, including a
important visceral
complete history, physical
compromise leading to a
examination, laboratory tests,
clinical indication for a
and imaging of chest and
more rapidly efficacious
abdomen (preferably CT
therapy, particularly since
scans) and bone, prior to
another treatment option
initiation of systemic
at progression will probably
therapy, is highly
not be possible.
recommended.
Primary endocrine resistance Expert opinion 66.6% (22) Yes
PETCT, if available, may be IIB 100% (37) yes
is defined as: a relapse 21.2% (7) abstain
used (instead of and not on 0% (0) abstain
while on the first 2 years of (33 voters)
top of CT scans and bone (37 voters)
adjuvant ET, or PD within
scan).
first 6 months of first-line
Systemic therapy (not surgery Expert 100% (40) yes
ET for MBC, while on ET
or radiotherapy) should be opinion 0% (0) abstain
Secondary (acquired)
the initial treatment. If LABC (40 voters)
endocrine resistance is
remains inoperable after
defined as: a relapse while
systemic therapy and
on adjuvant ET but after
eventual radiation, palliative
the first 2 years, or a relapse
mastectomy should not be
within 12 months of
done, unless the surgery is
completing adjuvant ET, or
likely to result in an overall
PD 6 months after
improvement in quality of
initiating ET for MBC,
life.
while on ET.
A combined treatment IA 100% (39) yes
modality based on a 0% (0) abstain
LoE: available level of evidence; consensus: percentage of panel
multidisciplinary approach (39 voters)
members in agreement with the statement; ET: endocrine therapy;
(systemic therapy, surgery,
PD: progressive disease; MBC: metastatic breast cancer.
and radiotherapy) is strongly
Continued
| Cardoso et al.
Annals of Oncology special article
Continued IV. inoperable, locally advanced
Guideline statements LoE Consensus
inammatory, breast cancer
indicated in the vast majority
of cases.
For triple-negative LABC, IA 85.3% (35) yes Guideline statements LoE Consensus
anthracycline- and taxane- 9.7% (4) abstain
based chemotherapy is (41 voters) For inflammatory LABC, IB 92.6% (38) yes
recommended as an initial overall treatment 4.8% (2) abstain
treatment. recommendations are (41 voters)
For HER-2-positive LABC, IA 91.8% (34) yes similar to those for non-
concurrent taxane and anti- 5.4% (2) abstain inflammatory LABC, with
HER-2 therapy is (37 voters) systemic therapy as a first
recommended since it treatment.
increases the rate of Mastectomy with axillary IB 95.1% (39) yes
pathological complete dissection is recommended 4.8% (2) abstain
response (pCR). in almost all cases, even (41 voters)
For HER-2-positive LABC, IA 71.7% (28) yes when there is a good
anthracycline-based 12.8% (5) response to primary
doi:10.1093/annonc/mdu385 |
special article Annals of Oncology
| Cardoso et al.
Annals of Oncology special article
when an aromatase inhibitor needs to be used in male ABC Continued
patients, a concomitant luteinizing-hormonereleasing hormone
agonist or orchiectomy should be added to further down-regulate Guideline statements LoE Consensus
testicular function. restaging, including assessment
of chest, abdomen, and bone.
Chest wall and regional recurrences IB 97.3% (37) yes
VI. specic sites of metastases should be treated with surgical 2.6% (1)
excision when feasible with a abstain
limited risk of morbidity. (38 voters)
Locoregional radiotherapy is IB 97.3% (37) Yes
Guideline statements LoE Consensus indicated for patients not 2.6% (1)
Prospective randomized clinical Expert 83.3% (25) yes previously irradiated. abstain
trials of local therapy for breast opinion 16.6% (5) (38 voters)
cancer liver metastases are (30 voters) For patients previously irradiated, Expert 97.3% (37) yes
urgently needed, since available re-irradiation of all or part of the opinion 2.6% (1)
evidence comes only from series chest wall may be considered in abstain
in highly selected patients. Since selected cases. (38 voters)
there are no randomized data In addition to local therapy (surgery IB 94.8% (37) yes
supporting the effect of local and/or RT), in the absence of 5.1% (2)
doi:10.1093/annonc/mdu385 |
special article Annals of Oncology
considered. Therapy can include surgical excision alone, surgical VII. update on ER-positive/
excision followed by radiation therapy, radiation therapy alone HER-2-negative ABC
(when surgical excision is not feasible), or concurrent chemother-
apy and radiation. Complete surgical resection reduces the total
required dose of radiation therapy and also maximizes the likeli- Guideline statements LoE Consensus
hood of long-term disease control. Complete excision alone can The preferred first-line ET for IA 83.3% (30) yes
lead to a 5-year disease-free survival rate of 35% [58]. Complete re- postmenopausal patients is an 16.6% (6) abstain
section followed by locoregional radiotherapy results in a 5-year aromatase inhibitor or tamoxifen, (36 voters)
localregional control ranging from 60% to 77% [59, 60]. Long- depending on the type and duration of
term predictors of disease-free survival after a localregional recur- adjuvant ET.
rence include a disease-free interval of >24 months and a complete Fulvestrant HD is also an option. IB 83.3% (30) yes
excision [59]. 16.6% (6) abstain
With modern radiotherapy techniques, it is often possible to (36 voters)
re-irradiate with full dose without too many side-effects [61]. The addition of everolimus to an IB 100% yes
The rst results of retreatment with stereotactic body radiother- aromatase inhibitor is a valid option (30 voters)
apy techniques have been published recently, describing promis- for some postmenopausal patients
ing local control rates [62]. with disease progression after a non-
Concurrent chemoradiation has both preclinical rationale and steroidal aromatase inhibitor, since it
clinical efcacy in many solid tumour types. Potential mechan- significantly prolongs PFS by a
| Cardoso et al.
Annals of Oncology special article
translocations), and upregulation of alternative pathways, such as Continued
the HER growth factor pathways and the PI3K/Akt/mammalian
target of rapamycin (mTOR) pathway. Guideline statements LoE Consensus
The mTOR inhibitor everolimus when added to exemestane, lapatinib + capecitabine) and beyond
in patients progressing on non-steroidal aromatase inhibitor, (versus treatment of physicians choice).
provided a signicant PFS prolongation of about 5 months [89, T-DM1 should be preferred in patients
90]. The overall survival data, presented after ABC2, demon- who have progressed through at least one
strated a non-signicant 4-month increase in median survival line of trastuzumab-based therapy, since
(HR 0.89) [91]. Overall survival prolongation was also observed, it provides an OS benefit.
in an exploratory analysis of the randomized phase II TAMRAD All patients with HER-2 + MBC who IB 87.5% (35) yes
study comparing the combination of tamoxifen and everolimus relapse after adjuvant anti-HER-2 12.5% (5) abstain
to tamoxifen alone in aromatase inhibitor (AI)-resistant patients therapy should be considered for further (40 voters)
[92]. These benets must be weighed against relevant toxicities anti-HER-2 therapy, except in the
associated with this compound, particularly stomatitis, pneu- presence of contraindications.
monitis, and hyperglycaemia. Decisions on everolimus use must The choice of the anti-HER-2 agent will
thus be made on a case-by-case basis, after discussion with a depend on country-specific availability,
the specific anti-HER-2 therapy
well-informed patient, and administered by physicians experi-
previously administered, and the relapse-
enced in managing adverse effects of this compound.
free interval.
doi:10.1093/annonc/mdu385 |
special article
| Cardoso et al.
Table 2. Advanced breast cancer (ABC)1 statements [10] with minor update or with no update
LoE Consensus
General recommendations
The management of ABC is complex and, therefore, involvement of all appropriate specialties in a multidisciplinary team (including but not restricted to medical, Expert opinion 100% (29) yes
radiation, surgical oncologists, imaging experts, pathologists, gynaecologists, psycho-oncologists, social workers, nurses, and palliative care specialists) is crucial. 0% (0) abstain
(29 voters)
From the time of diagnosis of ABC, patients should be offered appropriate psychosocial care, supportive care, and symptom-related interventions as a routine part Expert opinion 100% (30) yes
of their care. The approach must be personalized to meet the needs of the individual patient. 0% (0) abstain
(30 voters)
Following a thorough assessment and confirmation of metastatic breast cancer (MBC), the potential treatment goals of care should be discussed. Patients should be Expert opinion 97% (29) yes
told that MBC is incurable but treatable, and that some patients can live with MBC for extended periods of time (many years in some circumstances). 3% (1) abstain
This conversation should be conducted in accessible language, respecting patient privacy and cultural differences, and whenever possible, written information (30 voters)
should be provided.
Patients (and their families, caregivers, or support network, if the patient agrees) should be invited to participate in the decision-making process at all times. When Expert opinion 100% (30) yes
possible, patients should be encouraged to be accompanied by persons who can support them and share treatment decisions (e.g. family members, caregivers, 0% (0) abstain
and support network). (30 voters)
There are few proven standards of care in ABC management. After appropriate informed consent, inclusion of patients in well-designed, prospective, randomized Expert opinion 100% (30) yes
independent trials must be a priority whenever such trials are available and the patient is willing to participate. 0% (0) abstain
(30 voters)
The medical community is aware of the problems raised by the cost of ABC treatment. Balanced decisions should be made in all instances; patients well-being, Expert opinion 100% (32) yes
length of life, and preferences should always guide decisions. 0% (0) abstain
(32 voters)
Assessment guidelines
Minimal staging workup for MBC includes a history and physical examination, haematology and biochemistry tests, and imaging of chest, abdomen, and bone. 2C 67% (20) yes
3% (1) abstain
(30 voters)
Brain imaging should not be routinely carried out in asymptomatic patients. This approach is applicable to all patients with MBC including those patients with Expert opinion 94% (30) yes
HER-2+ and/or triple-negative breast cancer MBC. 0% abstain
(32 voters)
The clinical value of tumour markers is not well established for diagnosis or follow-up after adjuvant therapy, but their use is reasonable (if elevated) as an aid to 2C 89% (24) yes
evaluate response to treatment, particularly in patients with non-measurable metastatic disease. A change in tumour markers alone should not be used to initiate 4% (1) abstain
a change in treatment. (27 voters)
Evaluation of response to therapy should generally occur every 24 months for endocrine therapy (ET) or after two to four cycles for chemotherapy (CT), Expert opinion 81% (25) yes
depending on the dynamics of the disease, the location and extent of metastatic involvement, and type of treatment. 10% (3) abstain
Imaging of a target lesion may be sufficient in many patients. In certain patients, such as those with indolent disease, less frequent monitoring is acceptable. (31 voters)
Additional testing should be carried out in a timely manner, irrespective of the planned intervals, if progressive disease is suspected or new symptoms appear.
Annals of Oncology
Thorough history and physical examination must always be performed.
A biopsy (preferably providing histology) of a metastatic lesion should be carried out, if easily accessible, to confirm diagnosis particularly when metastasis is 1Ca 96% (27) yes
diagnosed for the first time. 0% (0) abstain
(28 voters)
special article
Anti-HER-2 therapy should be offered early to all patients with HER-2+ MBC, except in the presence of contraindications to the use of such therapy. IA 91% (30) yes
3% (1) abstain
doi:10.1093/annonc/mdu385 |
(33 voters)
For patients with ER+/HER-2+ MBC for whom ET was chosen over CT, anti-HER-2 therapy + ET should be considered with the initiation of ET (provided that IA 90% (27) yes
further anti-HER-2 therapy is available) since anti-HER-2 therapy (either trastuzumab or lapatinib) in combination with ET has shown substantial progression- 10% (3) abstain
free survival (PFS) benefit (i.e. time without CT) compared with ET alone. The addition of anti-HER-2 therapy in this setting has not led to a survival benefit. (30 voters)
Patients whose tumours progress on an anti-HER-2 therapy combined with a cytotoxic or endocrine agent should be offered additional anti-HER-2 therapy with IB 97% (29) yes
subsequent treatment since it is beneficial to continue suppression of the HER-2 pathway. 0% (0) abstain
The optimal duration of anti-HER-2 therapy for MBC (i.e. when to stop these agents) is currently unknown. (30 voters)
Continued
special article
| Cardoso et al.
LoE Consensus
Patients who have received any type of (neo)adjuvant anti-HER-2 therapy should not be excluded from clinical trials for HER-2+ MBC. IB 100% (23) yes
0% (0) abstain
(27 voters)
In the case of progression on trastuzumab, the combination of trastuzumab + lapatinib is also a reasonable treatment option in the course of the disease. IB 83% (24) yes
10% (3) abstain
(29 voters)
Chemotherapy and biological therapy
In the absence of medical contraindications or patient concerns, anthracycline- or taxane-based regimens, preferably as a single agent, would usually be considered IA 71% (17) yes
as first-line CT for HER-2-negative MBC, in those patients who have not received these regimens as adjuvant treatment and for whom chemotherapy is 4% (1) abstain
appropriate. Other options are, however, available and effective, such as capecitabine and vinorelbine, particularly if avoiding alopecia is a priority for the patient. (24 voters)
In patients with taxane-naive and anthracycline-resistant MBC or with anthracycline cumulative dose or toxicity (i.e. cardiac) who are being considered for further IA 59% (14) yes
CT, taxane-based therapy, preferably as a single agent, would usually be considered as the treatment of choice. Other options are, however, available and effective, 8% (2) abstain
such as capecitabine and vinorelbine, particularly if avoiding alopecia is a priority for the patient. (24 voters)
If given in the adjuvant setting, a taxane can be re-used in the metastatic setting, particularly if there has been at least 1 year of disease-free survival. IA 92% (22) yes
8% (2) abstain
(24 voters)
Duration of each regimen and the number of regimens should be tailored to each individual patient. Expert opinion 96% (26) yes
0% (0) abstain
(27 voters)
Usually each regimen (except anthracyclines) should be given until progression of disease or unacceptable toxicity. IB 72% (21) yes
What is considered unacceptable should be defined together with the patient. 7% (2) abstain
(29 voters)
Bevacizumab combined with chemotherapy as first- or second-line therapy for MBC provides only a moderate benefit in PFS and no benefit in overall survival. The IA 74% (17) yes
absence of known predictive factors for bevacizumab efficacy renders recommendations on its use difficult. Bevacizumab can only therefore be considered as an 17% (4) abstain
option in selected cases in these settings and is not recommended after a first/second line. (23 voters)
Neurological symptoms and signs, which suggest the possibility of spinal cord compression, must be investigated as a matter of urgency. This requires a full IB 100% (24) yes
radiological assessment of potentially affected area as well as adjacent areas of the spine. MRI is the method of choice. An emergency surgical opinion 0% (0) abstain
Annals of Oncology
(neurosurgical or orthopaedic) may be required for surgical decompression. If no decompression/stabilization is feasible, emergency radiotherapy is the (24 voters)
treatment of choice and vertebroplasty is also an option.
Patients with a single or small number of potentially resectable brain metastases should be treated with surgery or radiosurgery. Radiosurgery is an option for some IB 92% (22) yes
unresectable brain metastases. 4% (1) abstain
(24 voters)
For ER+ male MBC, tamoxifen is the preferred option. Expert opinion 83% (15) yes
6% (1) abstain
(18 voters)
special article
doi:10.1093/annonc/mdu385 |
a
LoE changed since ABC1 from 2C to 1C based on new published data [128130].
5%, respectively). PFS, a secondary end point, was lower in the Continued
lapatinib arm (6.6 versus 8.0 months).
Additional evidence comes from the adjuvant ALTTO trial, Guideline statements LoE Consensus
where the lapatinib-alone arm was closed early, due to futility in In patients pre-treated (in the adjuvant or IB 77.1% (27) yes
a non-inferiority comparison to trastuzumab, and patients metastatic setting) with an anthracycline 20.0% (7) abstain
offered cross-over to receive trastuzumab [95]. and a taxane, and who do not need (35 voters)
The CLEOPATRA trial [96, 97] showed superior results, in combination chemotherapy, single-agent
terms of PFS (18.5 versus 12.4 months) and 1-year survival (23.6% capecitabine, vinorelbine, or eribulin are
versus 17.2%), of the triplet trastuzumab + pertuzumab + docetaxel the preferred choices.
compared with trastuzumab + docetaxel as rst-line therapy. Additional choices include gemcitabine,
Importantly, the majority (90%) of the patients were trastuzu- platinum agents, taxanes, and liposomal
mab-naive; if previously treated with trastuzumab, a 12-month anthracyclines.
disease-free interval was required. Therefore, this trial did not The decision should be individualized and
address, and therefore cannot support, the use of this combination take into account different toxicity
in patients with truly trastuzumab-resistant tumours. There are also profiles, previous exposure, patient
no data supporting the use of the dual blockade with trastuzumab preferences, and country availability.
+ pertuzumab with CT beyond rst line, after treatment with
LoE: available level of evidence; consensus: percentage of panel
trastuzumab + pertuzumab + CT in the rst line (i.e. continuing a
members in agreement with the statement; CT: chemotherapy.
dual blockade beyond progression) and, therefore, this regimen
Continued Continued
| Cardoso et al.
Annals of Oncology special article
Continued several steps of their care, but emphasize that much remains to
be done. Implementation of guidelines is very heterogeneous
Guideline statements LoE Consensus between countries but also within countries, according to the
surgery is only valuable if carried out with environment where the patient is treated and cost of treatment.
the same attention to detail (e.g. attaining The complexity of this disease, the multiple factors that must
clear margins and addressing disease in the be taken into account, the lack of high-level evidence for several
axilla) as in patients with early stage disease. clinical situations, and new highly specialized techniques avail-
able for local management of specic sites of metastases, all con-
LoE: available level of evidence; consensus: percentage of panel stitute strong reasons for the treatment of these patients by a
members in agreement with the statement. specialized multidisciplinary team, rather than management by
an isolated oncologist regardless of his/her skills or experience.
Our plea for a strong commitment of all involved parties (aca-
Available data regarding the value of removal of the primary demia, pharmaceutical industry, independent funding sources,
tumour in patients with stage IV at diagnosis were extensively and advocacy groups) to develop well-designed, high-quality
reviewed and published in one of the ESO-ABC Task Force multidisciplinary (involving other issues than drug-development)
manuscripts [13]. All but one study published after this 2010 trials for ABC remains of critical importance. Many questions
paper support the surgical removal of the primary tumour in are still unanswered, related to management strategies, optimal
patients with stage IV disease, reinforcing the importance of the drug use, and individualized treatment (based on predictive
ongoing prospective trials evaluating this approach since existing markers and eventually new technologies aiming at better char-
doi:10.1093/annonc/mdu385 |
special article Annals of Oncology
10. Cardoso F, Costa A, Norton L et al. 1st International consensus guidelines for 33. Yamauchi H, Woodward WA, Valero V et al. Inammatory breast cancer: what we
advanced breast cancer (ABC1). The Breast 2012; 21(3): 242252. know and what we need to learn. Oncologist 2012; 17: 891899.
11. Metastatic breast cancer. Recommendations proposal from the European School 34. Brennan ME, Houssami N. Evaluation of the evidence on staging imaging for
of Oncology (ESO)-MBC Task Force. The Breast 2007; 16: 910. detection of asymptomatic distant metastases in newly diagnosed breast cancer.
12. Cardoso F, Bedard PL, Winer EP et al. International guidelines for management of The Breast 2012; 21: 112123.
metastatic breast cancer: combination vs sequential single-agent chemotherapy. 35. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a
J Natl Cancer Inst 2009; 101: 11741181. monoclonal antibody against HER2 for metastatic breast cancer that
13. Pagani O, Senkus-Konefka E, Wood W et al. International guidelines for overexpresses HER2. N Engl J Med 2001; 344(11): 783792.
management of metastatic breast cancer (MBC) from the European School of 36. Buzdar AU, Suman V, Bernstam F. ACOSOG Z1041 (Alliance): denitive analysis
Oncology (ESO)-MBC Task Force: can metastatic breast cancer be cured? J Natl of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus
Cancer Inst 2010; 102: 18. trastuzumab (FEC P + T) with paclitaxel plus trastuzumab followed by FEC plus
14. Lin NU, Thomssen C, Cardoso F et al. International guidelines for management of trastuzumab (P + T FEC + T) in HER2+ operable breast cancer. Lancet Oncol
metastatic breast cancer (MBC) from the European School of Oncology (ESO) 2013; 14(13): 1317.
MBC Task Force: Surveillance, Staging, and Evaluation of Patients with Early- 37. Ellis MJ, Suman VJ, Hoog J et al. Randomized phase II neoadjuvant comparison
Stage and Metastatic Breast Cancer. The Breast 2013; 22(3): 203210. between letrozole, anastrozole, and exemestane for postmenopausal women with
15. Guyatt G, Gutterman D, Baumann MH et al. Grading strength of estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker
recommendations and quality of evidence in clinical guidelines: report from an outcomes and predictive value of the baseline PAM50-based intrinsic subtype
American College of Chest Physicians task force. Chest 2006; 129(1): 174181. ACOSOG Z1031. J Clin Oncol 2011; 29: 23422349.
16. Freeman HP. Patient navigation: a community centered approach to reducing 38. Cataliotti L, Buzdar AU, Noguchi S et al. Comparison of anastrozole versus
cancer mortality. J Cancer Educ 2006; 21(1 suppl): S11S14. tamoxifen as preoperative therapy in postmenopausal women with hormone
17. Freund KM, Battaglia TA, Calhoun E et al. National Cancer Institute Patient receptor-positive breast cancer: the PRe-Operative Arimidex Compared to
| Cardoso et al.
Annals of Oncology special article
52. Alba E, Chacon J, Lluch A et al. A randomized phase II trial of platinum salts in 76. Aebi S et al. Chemotherapy for isolated locoregional recurrence of breast cancer
basal-like breast cancer patients in the neoadjuvant setting. Results from the (CALOR): a randomized trial. Lancet Oncol 2014; 15(2): 156163.
GEICAM/2006-03, multicenter study. Breast Cancer Res Treat 2012; 136(2): 77. Robertson JF, Osborne CK, Howell A et al. Fulvestrant versus anastrozole for the
487493. treatment of advanced breast carcinoma in postmenopausal women: a
53. Koshy N, Quispe D, Shi R et al. Cisplatin-gemcitabine therapy in metastatic prospective combined analysis of two multicenter trials. Cancer 2003; 98(2):
breast cancer: improved outcome in triple negative breast cancer patients 229238.
compared to non-triple negative patients. Breast 2010; 19(3): 246248. 78. Howell A, Pippen J, Elledge RM et al. Fulvestrant versus anastrozole for the
54. Hemsell DL, Grodin JM, Brenner PF et al. Plasma precursors of oestrogen II. treatment of advanced breast carcinoma: a prospectively planned combined
Correlation of the extent of conversion of plasma androstenedione to estrone with survival analysis of two multicenter trials. Cancer 2005; 104(2): 236239.
age. J Clin Endocrinol Metab 1974; 38: 476479. 79. Chia S, Gradishar W, Mauriac L et al. Double-blind, randomized placebo
55. Handesman D. Androgen Actions and Pharmacologic Uses, Endocrinology. controlled trial of fulvestrant compared with exemestane after prior nonsteroidal
Philadelphia: WB Saunders, 2001; 22322242. aromatase inhibitor therapy in postmenopausal women with hormone receptor-
56. Sousa B, Moser E, Cardoso F. An update on male breast cancer and future positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008; 26
directions for research and treatment. Eur J Pharmacol 2013; 717: 7183. (10): 16641670.
57. Nordman IC, Dalley DN. Breast cancer in menshould aromatase inhibitors 80. Di Leo A, Jerusalem G, Petruzelka L et al. Results of the CONFIRM phase III trial
become rst-line hormonal treatment? Breast J 2008; 4: 562569. comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal
58. Faneyte IF, Turgers EJ, Zoetmulder FA. Chest wall resection in the treatment of women with estrogen receptor-positive advanced breast cancer. J Clin Oncol
locally recurrent breast carcinoma: indications and outcome for 44 patients. 2010; 28(30): 45944600.
Cancer 1997; 80(5): 886. 81. Johnston SR, Kilburn LS, Ellis P et al. Fulvestrant plus anastrozole or placebo
59. Schwaibold F, Fowble BL, Solin LJ et al. The results of radiation therapy for versus exemestane alone after progression on non-steroidal aromatase inhibitors
isolated local regional recurrence after mastectomy. Int J Radiat Oncol Biol Phys in postmenopausal patients with hormone-receptor-positive locally advanced or
doi:10.1093/annonc/mdu385 |
special article Annals of Oncology
93. Gelmon KA, Boyle F, Kaufman B et al. Open-label phase III randomized controlled 110. Blum JL, Jones SE, Buzdar AU et al. Multicenter phase II study of capecitabine in
trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1996; 17: 485493.
trastuzumab (T) as rst-line therapy for women with HER-2 metastatic breast 111. Blum JL, Dieras V, Lo Russo PM et al. Multicenter, phase II study of capecitabine
cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. J Clin Oncol in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001; 92:
2012; 30 (Suppl: LBA671). 17591768.
94. Pivot X, Semiglazov V, Zurawski V et al. CEREBEL (EGF111438): an open label 112. Miller KD, Chap LI, Holmes FA et al. Randomized phase III trial of capecitabine
randomized phase III study comparing the incidence of CNS metastases in compared with bevacizumab plus capecitabine in patients with previously treated
patients with HER2+ metastatic breast cancer, treated with lapatinib plus metastatic breast cancer. J Clin Oncol 2005; 23: 792799.
capecitabine versus trastzumab pluas capecitabine. Ann Oncol 2012; 23(Suppl 113. Andersson M, Lidbrink E, Bjerre K et al. Phase III randomized study comparing
9): ixe1ixe30. docetaxel plus trastuzumab with vinorelbine plus trastuzumab as rst-line therapy
95. Piccart-Gebhart M, Holmes AP, Baselga J et al. First results from the phase III of metastatic or locally advanced human epidermal growth factor receptor
ALTTO trial (BIG 02-06; NCCTG 063D) comparing one year of anti-HER2 therapy 2-positive breast cancer: The HERNATA Study. J Clin Oncol 2010; 29: 264271.
with lapatinib alone (L), trastuzumab alone (T), their sequence (TL) or their 114. Burstein HJ, Keshaviah A, Baron AD et al. Trastuzumab plus vinorelbine or taxane
combination (L + T) in the adjuvant treatment of HER2-positive early breast chemotherapy for HER2-overexpressing metastatic breast cancer: the
cancer (EBC). J Clin Oncol 2014; 32 (Suppl 5s; abstr LBA4). trastuzumab and vinorelbine or taxane study. Cancer 2007; 110(5): 965972.
96. Baselga J, Cortes J, Kim SB et al. Pertuzumab plus trastuzumab plus docetaxel 115. Cortes J, OShaughnessy J, Loesch D et al. Eribulin monotherapy versus treatment
for metastatic breast cancer. N Engl J Med 2012; 366: 109119. of physicians choice in patients with metastatic breast cancer (EMBRACE): a phase
97. Swain SM et al. Conrmatory overall survival (OS) analysis of CLEOPATRA: a 3 open-label randomised study. Lancet 2011; 377(9769): 914923.
randomized, double-blind, placebo controlled Phase III study with pertuzumab 116. Kaufman PA, Awada A, Twelves C et al. A Phase III, open-label, randomized,
(P), trastuzumab (T), and docetaxel (D) in patients ( pts) with HER2-positive rst- multicenter study of eribulin mesylate versus capecitabine in patients with locally
line (1L) metastatic breast cancer (MBC). Lancet Oncol 2013; 14(6): 461471. advanced or metastatic breast cancer previously treated with anthracyclines and
| Cardoso et al.